Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
In 2017, the Food and Drug Administration approved a new iteration, Ozempic (semaglutide), as a T2D treatment
NICE flags as the better target
Imbruvica (ibrutinib) Disease area(s): Oncology/hematology Manufacturer(s): AbbVie/Johnson & Johnson 2024 Sales (USD): $6.39 billion Why it sold so well: In 2024, Johnson & Johnson saw a 7% decline in global revenues of Imbruvica, primarily due to decreased demand and lower market share in the US, as well as reduced collaboration revenues internationally
include: Exenatide (Byetta, Bydureon) Dulaglutide (Trulicity) Lixisenatide (Adlyxin) Liraglutide (Victoza, Saxenda) Semaglutide (Ozempic, Wegovy, Rybelsus) Compare Rybelsus vs Ozempic
US$ 23.93
US$ 21.99
US$ 20.55
US$ 22.02
US$ 23.98
US$ 28.09
